Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 12907 | 810 | 42.3 | 82% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 151 | 22214 | IMMUNOTHERAPY//DENDRITIC CELLS//CANCER IMMUNOLOGY IMMUNOTHERAPY |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | IDIOTYPE | Author keyword | 50 | 41% | 11% | 93 |
| 2 | IDIOTYPE VACCINATION | Author keyword | 17 | 100% | 1% | 8 |
| 3 | CELL THER Y AREA | Address | 6 | 45% | 1% | 10 |
| 4 | IMMUNOGLOBULIN IDIOTYPES | Author keyword | 4 | 75% | 0% | 3 |
| 5 | UNIV NAVARRA HOSP | Address | 3 | 100% | 0% | 3 |
| 6 | IDIOTYPE VACCINE | Author keyword | 3 | 40% | 1% | 6 |
| 7 | KG JEBSEN INFLUENZA VACCINES | Address | 3 | 45% | 1% | 5 |
| 8 | IDIOTYPIC VACCINATION | Author keyword | 3 | 50% | 0% | 4 |
| 9 | IDIOTYPE VACCINES | Author keyword | 3 | 60% | 0% | 3 |
| 10 | LYMPHOMA IMMUNOTHERAPY | Author keyword | 3 | 60% | 0% | 3 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | IDIOTYPE | 50 | 41% | 11% | 93 | Search IDIOTYPE | Search IDIOTYPE |
| 2 | IDIOTYPE VACCINATION | 17 | 100% | 1% | 8 | Search IDIOTYPE+VACCINATION | Search IDIOTYPE+VACCINATION |
| 3 | IMMUNOGLOBULIN IDIOTYPES | 4 | 75% | 0% | 3 | Search IMMUNOGLOBULIN+IDIOTYPES | Search IMMUNOGLOBULIN+IDIOTYPES |
| 4 | IDIOTYPE VACCINE | 3 | 40% | 1% | 6 | Search IDIOTYPE+VACCINE | Search IDIOTYPE+VACCINE |
| 5 | IDIOTYPIC VACCINATION | 3 | 50% | 0% | 4 | Search IDIOTYPIC+VACCINATION | Search IDIOTYPIC+VACCINATION |
| 6 | IDIOTYPE VACCINES | 3 | 60% | 0% | 3 | Search IDIOTYPE+VACCINES | Search IDIOTYPE+VACCINES |
| 7 | LYMPHOMA IMMUNOTHERAPY | 3 | 60% | 0% | 3 | Search LYMPHOMA+IMMUNOTHERAPY | Search LYMPHOMA+IMMUNOTHERAPY |
| 8 | DONOR VACCINATION | 2 | 67% | 0% | 2 | Search DONOR+VACCINATION | Search DONOR+VACCINATION |
| 9 | B LYMPHOMA | 2 | 17% | 1% | 9 | Search B+LYMPHOMA | Search B+LYMPHOMA |
| 10 | DENDRITIC CELL VACCINES | 2 | 33% | 0% | 4 | Search DENDRITIC+CELL+VACCINES | Search DENDRITIC+CELL+VACCINES |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | IDIOTYPE VACCINATION | 71 | 61% | 9% | 76 |
| 2 | IDIOTYPIC VACCINATION | 20 | 66% | 2% | 19 |
| 3 | TRANSPLANTATION RESISTANCE | 15 | 77% | 1% | 10 |
| 4 | FC RECEPTOR GENOTYPE | 11 | 100% | 1% | 6 |
| 5 | SOMATIC VARIANTS | 11 | 100% | 1% | 6 |
| 6 | ANTIIDIOTYPIC T CELLS | 9 | 83% | 1% | 5 |
| 7 | TUMOR ESCAPE MECHANISM | 8 | 75% | 1% | 6 |
| 8 | SURFACE IMMUNOGLOBULIN IDIOTYPE | 7 | 67% | 1% | 6 |
| 9 | TCR VACCINES | 6 | 80% | 0% | 4 |
| 10 | MYELOMA PROTEINS | 5 | 26% | 2% | 17 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Vaccines for lymphomas: Idiotype vaccines and beyond | 2009 | 36 | 29 | 66% |
| Anti-idiotype antibodies in cancer treatment | 2007 | 29 | 58 | 64% |
| Idiotype Vaccines for Human B-Cell Malignancies | 2010 | 7 | 84 | 81% |
| How do CD4(+) T cells detect and eliminate tumor cells that either lack or express MHC class II molecules? | 2014 | 10 | 95 | 23% |
| Immunodeficiency and immunotherapy in multiple myeloma | 2007 | 77 | 162 | 26% |
| Current status of therapeutic vaccines for non-Hodgkin's lymphoma | 2005 | 29 | 59 | 58% |
| Variations in "rescuability" of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development | 2004 | 11 | 20 | 80% |
| Lymphoma Vaccine Therapy: Next Steps After a Positive, Controlled Phase III Clinical Trial | 2012 | 2 | 28 | 71% |
| Idiotype vaccines for lymphoma therapy | 2011 | 2 | 40 | 75% |
| Therapeutic idiotype vaccines in B lymphoproliferative diseases | 2004 | 9 | 34 | 76% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | CELL THER Y AREA | 6 | 45% | 1.2% | 10 |
| 2 | UNIV NAVARRA HOSP | 3 | 100% | 0.4% | 3 |
| 3 | KG JEBSEN INFLUENZA VACCINES | 3 | 45% | 0.6% | 5 |
| 4 | ADULT ONCOLDIS HEMATOL ONCOL | 2 | 67% | 0.2% | 2 |
| 5 | OFF SCI OPERAT | 2 | 67% | 0.2% | 2 |
| 6 | UNITE UP 2021 | 2 | 67% | 0.2% | 2 |
| 7 | BACTERIOL INFECT IMMUNOL | 1 | 50% | 0.2% | 2 |
| 8 | DHMO | 1 | 50% | 0.2% | 2 |
| 9 | GEN FLOW CYTOMETRY SERV | 1 | 100% | 0.2% | 2 |
| 10 | UNITE UMR BIOTECHNOL SIGNALISAT CELLULAIRE | 1 | 100% | 0.2% | 2 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000108878 | DENDRITIC CELLS//DENDRITIC CELL//TUMOR LYSATE |
| 2 | 0.0000101781 | ANTI IDIOTYPIC ANTIBODY//ANTI ANTI IDIOTYPIC ANTIBODY//INTERNAL IMAGE |
| 3 | 0.0000101754 | PRAME//LEUKEMIA ASSOCIATED ANTIGENS//UNIT 900 |
| 4 | 0.0000080247 | DNA VACCINE//DNA VACCINES//DNA IMMUNIZATION |
| 5 | 0.0000079840 | IG ALLOTYPE//UNITE IMMUNOPHYSIOL MOL//DEXTRAN B512 |
| 6 | 0.0000070460 | CD20//OFATUMUMAB//OBINUTUZUMAB |
| 7 | 0.0000060536 | PLASMA CELL LEUKEMIA//PRIMARY PLASMA CELL LEUKEMIA//MMSET |
| 8 | 0.0000058881 | CANCER TESTIS ANTIGEN//CANCER TESTIS ANTIGENS//NY ESO 1 |
| 9 | 0.0000056122 | CCDC134//TUMOR IMMUN TOLERANCE SECT//ANTIGEN SPECIFIC CTL FUNCTION |
| 10 | 0.0000053500 | BISPECIFIC ANTIBODIES//CATUMAXOMAB//TRIFUNCTIONAL ANTIBODY |